The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are: Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry? Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment. Participants will: * Take NAM or a placebo every day for 2 years * Visit the clinic once every 3-4 months for checkups and tests
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean Deviation (MD)
Timeframe: 2 years